CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: We next evaluated the toxicity of metformin at millimole level on normal CD34+ and observed less death and CFC impair of normal CD34+ compared to its CML counterpart (Fig. 3D, E), indicating a therapeutic window.